Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Wed, 03.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 03, 2023
MorphoSys AG Reports First Quarter 2023 Financial Results
Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023
Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2 [ … ]
Wed, 03.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 03, 2023
MorphoSys AG Reports First Quarter 2023 Financial Results
Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023
Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2 [ … ]
Thu, 27.04.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, April 27, 2023
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).
MorphoSys' Management team will host a [ … ]
Thu, 27.04.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, April 27, 2023
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).
MorphoSys' Management team will host a [ … ]
Sun, 16.04.2023
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual M [ … ]
Sun, 16.04.2023
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual M [ … ]
Tue, 04.04.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, April 4, 2023
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
Enrollment of Phase 3 frontMIND study of tafasitamab in first-line diffuse large B-cell lymphoma is also complete
MorphoSys AG (FSE: MOR; NASDAQ: MOR) anno [ … ]
Tue, 04.04.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, April 4, 2023
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
Enrollment of Phase 3 frontMIND study of tafasitamab in first-line diffuse large B-cell lymphoma is also complete
MorphoSys AG (FSE: MOR; NASDAQ: MOR) anno [ … ]
Fri, 24.03.2023
MorphoSys AG
NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES"), AUSTRALIA, SOUTH AFRICA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLI [ … ]
Fri, 24.03.2023
MorphoSys AG
NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES"), AUSTRALIA, SOUTH AFRICA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLI [ … ]